Table 1.

Four retrospective case series looking at conversion surgery after chemotherapy for advanced/metastatic gastric cancer

First author	Time of accrual	Eligibility	Chemotherapeutic regimen	Indication for surgery	No. of patients who received chemotherapy	No. of patients who received gastrectomy	% treated by gastrectomy	No. of patients who received R0 resection	Rate of R0 resection among all surgeries	MST of patients who received surgery	MST of the R0 resected patients
Yamaguchi16	2001‐2013	cStage IV	Various doublets/triplets	R0 resection possible	259	84	32.4	43	51.2	30.5	41.3
Fukuchi17	2003‐2013	Any one of the following: cT4b, P1, H1, CY1, M1	S‐1/CDDP or S‐1/paclitaxel	R0 resection possible	151	40	26	32	80	53	62
Sato18	2002‐2014	cStage IV	S‐1/CDDP/docetaxel	R0 resection possible	100	33	33	28	85	47.8	47.9
Ishigami19	2005‐2011	P1 or CY1	S‐1/paclitaxel IV/paclitaxel IP	CY0, disappearance of shrinkage of peritoneal mets	100	64	64	44	68.8	30.5	NA

The fourth series was restricted to patients who underwent intraperitoneal chemotherapy for peritoneal metastases.

IP, intraperitoneal chemotherapy; mets, metastases; MST, median survival time (months); NA, not available.